0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXADR

CXADR

CXADR Molecule Information

Name:Calcium sensing receptor
Target Synonym:Extracellular calcium-sensing receptor,hCasR,GPRC2A,Calcium Sensing Receptor,Parathyroid Ca(2+)-Sensing Receptor 1,Severe Neonatal Hyperparathyroidism,Calcium-Sensing Receptor,HYPOC1,NSHPT,PCaR1,EIG8,HHC1,CaSR,CAR,FHH,FIH,HHC,Receptors, Calcium-Sensing,Hy
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

CXADR Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CXR-H5222 Human Human CXADR / CAR Protein, His Tag
CXR-H5222-structure
CXR-H5222-sds

CXADR Molecule Synonym Name

CXADR,CAR,CAR4/6,HCAR

CXADR Molecule Background

Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human

CXADR Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Parathyroid hormone (Shire) 423562; ALX-111; SHP-634; SHP-635; NPSP-558; NPSP-795; PTH 1-84; SB-423562; PTH (1-84); rhPTH-1-84; rhPTH (1-84) Approved Shire Natpar, Natpara, Preotact EU Hypoparathyroidism s:33:"Shire Pharmaceuticals Ireland Ltd"; 2006-04-24 Osteoporosis; Osteoporosis, Postmenopausal; Hypoparathyroidism Details
Etelcalcetide Hydrochloride AMG-416; KAI-4169; ONO-5163; KAI-4169-HCl Approved Amgen Inc Parsabiv United States Hyperparathyroidism, Secondary s:19:"Kai Pharmaceuticals"; 2016-11-11 Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic Details
Cinacalcet Hydrochloride AMG-073.HCl; AMG-073; KRN-1493; NPS-1493 Approved Amgen Inc Sensipar/Mimpara, 盖平, Mimpara, Parareg, Regpara, Sensipar Mainland China Hyperparathyroidism, Secondary; Hypercalcemia; Hyperparathyroidism s:17:"Kyowa Hakko Kirin"; 2004-03-08 Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hypophosphatemia; Nephrosis; Edema, Cardiac; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Renal Insufficiency, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Kidney Failure, Chronic Details
Strontium Ranelate FK-481; S-12911; S-12911-2 Approved Servier 欧思美, Osseor, Protos, Protelos Mainland China Osteoporosis, Postmenopausal s:24:"Les Laboratoires Servier"; 2004-09-20 Osteoporosis, Postmenopausal Details
Evocalcet MT-4580; KHK-7580 Approved Mitsubishi Tanabe Pharma Corp Orkedia Japan Hyperparathyroidism, Secondary s:17:"Kyowa Hakko Kirin"; 2018-03-23 Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism Details

CXADR Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LNP-1892 LNP-1892 Phase 2 Clinical Rubin Ltd Hyperparathyroidism Details
AJT-240 AJT-240; SK-1403 Phase 3 Clinical Ea Pharma Hyperparathyroidism, Secondary; Hyperparathyroidism Details
Encaleret sulfate MK-5442; JTT-305; CLTX-305 Phase 2 Clinical Japan Tobacco (Hong Kong) Ltd Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal Details
DS-9194b DS-9194b Phase 1 Clinical Daiichi Sankyo Co Ltd Osteoporosis Details

This web search service is supported by Google Inc.

totop